BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bio-Matrix Scientific Group Inc. (BMSN.OB)'s Majority Owned Subsidiary Entest Biomedical, Inc. Initiates Studies to Support Stem Cell / Laser Regenerative Therapy for COPD


2/2/2010 2:19:32 PM

SAN DIEGO, CA--(Marketwire - February 02, 2010) - Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) announced that its majority owned subsidiary, Entest BioMedical Inc. (OTCBB: ENTB) has initiated studies to support the Company's stem cell / laser regenerative therapy for Chronic Obstructive Pulmonary Disease (COPD).

According to a Company spokesperson, Entest has begun to research the effects of Low Energy Near Infrared Radiation on cultured cells as a step toward animal pre-clinical studies for the treatment of COPD. Studies will be an extension of current Entest intellectual property covering enhancement of stem cell growth and activity. Specific focus will be placed on type II alveolar epithelial cells and related stem cells known to reside in the lung.

Dr. Steve Josephs, Co-Principal Investigator for Entest, states, "We are pleased with the progress of our ENT-576 program which uses Low Level Laser (LLL) therapy for COPD as a means of inhibiting inflammation and stimulating lung regeneration. We view these studies as critical in determining the direction of our pre-clinical and clinical research."

Entest's Chairman & CEO David Koos, stated, "According to the COPD Foundation, every 4 minutes an American dies of COPD. It is estimated there are over 24 million cases of COPD in the US, of which 12 million people don't even know they have it. Our research represents hope for the future in curing COPD."

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT-576 is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD.

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is the majority owner of Entest BioMedical Inc. BMSN is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.

Forward-looking statements:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


Contact:

David R. Koos
Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax

Entest BioMedical Inc.
Email Contact
www.EntestBio.com

Bio-Matrix Scientific Group Inc.
www.BMSN.us
Email Contact

Follow the Company's progress on Twitter:

http://twitter.com/Entest_BioMed



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES